Allergan to pay $600 million settle US Botox probe;drops off-label suit
This article was originally published in Scrip
Officials at the US Department of Justice report that drug maker Allergan has agreed to plead guilty to a single misdemeanour charge and pay $600 million to resolve a years-long federal probe involving allegations of unlawful, off-label promotion of Botox (botulinum toxin A). By settling, the company has disappointed others in the industry, as it also agreed to drop a lawsuit filed against the FDA last year challenging a government rule that prohibited it from disseminating truthful information to physicians to assist them in evaluating risks and benefits of Botox for certain off-label uses. Allergan had wanted a declaration that such rules are unconstitutional, claiming it has a chilling effect on protected speech.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.